MedTrace Logo

Childhood Maltreatment, Traumatic Experiences and Stress-associated Parameters in Schizophrenia Spectrum Disorders

NCT03730831 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-08-13

No results posted yet for this study

Summary

Childhood maltreatment (CM) in psychotic disorders is associated with increased cognitive deficits, severe psychotic symptoms, and increased comorbidity. The number of different stress experiences also increases the probability of trauma-associated symptoms. Furthermore, neurobiological changes play a key role in the vulnerability of individuals with early traumas for mental and physical illnesses, among others for diseases of the schizophrenia spectrum disorder and the further course of the disease.

The project is divided into two work programs and pursues:

1. A detailed recording of the course of symptoms in participants with schizophrenia spectrum disorder to link this data with a systematic recording of CM and traumatic experiences and biological data.
2. On a subsample of participants with schizophrenia spectrum disorder and a comorbid post-traumatic stress disorder (PTSD), the researchers want to investigate whether symptom traits of existing psychotic disorders, trauma-associated symptoms and cognitive functions can be influenced by a trauma-specific treatment (NET), that has been proven to be effective in the treatment of PTSD.

Conditions

  • Schizophrenia Spectrum Disorder
  • PTSD

Interventions

BEHAVIORAL

Narrative Exposure Therapy

8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling -\> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder.

Sponsors & Collaborators

  • Centre for Psychiatry Reichenau

    collaborator UNKNOWN

  • University of Konstanz

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2022-10-24
Completion
2022-10-24

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03730831 on ClinicalTrials.gov